Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MREO 
Mereo BioPharma Group PLC ADR (MREO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: MREO (3-star) is a STRONG-BUY. BUY since 13 days. Profits (0.38%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $7.63
Year Target Price $7.63
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 66.86% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 422.94M USD | Price to earnings Ratio - | 1Y Target Price 7.7 |
Price to earnings Ratio - | 1Y Target Price 7.7 | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 1.57 - 5.02 | Updated Date 06/29/2025 |
52 Weeks Range 1.57 - 5.02 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.59% | Return on Equity (TTM) -91.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 361204767 | Price to Sales(TTM) 598.13 |
Enterprise Value 361204767 | Price to Sales(TTM) 598.13 | ||
Enterprise Value to Revenue 576.45 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 159000000 | Shares Floating 508721425 |
Shares Outstanding 159000000 | Shares Floating 508721425 | ||
Percent Insiders 0.96 | Percent Institutions 76.57 |
Analyst Ratings
Rating 4.75 | Target Price 7.63 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mereo BioPharma Group PLC ADR
Company Overview
History and Background
Mereo BioPharma Group PLC ADR (MREO) is a biopharmaceutical company focused on rare diseases and oncology. Founded in 2015, it acquires and develops mid- to late-stage clinical assets. It merged with OnKure in 2023, expanding its oncology pipeline.
Core Business Areas
- Rare Diseases: Development and commercialization of therapies for rare diseases, targeting unmet medical needs. Focus on conditions with limited treatment options.
- Oncology: Focus on developing cancer therapies, following the merger with OnKure.
Leadership and Structure
Denise Scots-Knight is the CEO. The company has a board of directors overseeing strategic direction. The organizational structure includes research & development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Alvelestat: An oral inhibitor of neutrophil elastase, for treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Alvelestat is in a Phase 3 trial. Competitors include CSL Behring's Zemaira and Grifols' Prolastin-C (Alpha-1 proteinase inhibitors).
- Etigilimab: An anti-TIGIT antibody for oncology, currently in Phase 1/2 clinical development. Competitors include Roche (TIGIT inhibitor tiragolumab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant market competition. Demand for novel therapies, particularly for rare diseases and cancer, is high.
Positioning
Mereo focuses on developing and acquiring assets with significant unmet medical needs. Their strategy involves de-risking drug development by focusing on mid-to late-stage assets.
Total Addressable Market (TAM)
The global market for AATD therapies is estimated at $1.5-2.0 billion. The oncology market is significantly larger, estimated at hundreds of billions of dollars annually. Mereo is positioned to capture a share of these markets, dependent on clinical success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focused strategy on rare diseases and oncology
- Mid- to late-stage clinical assets
- Experienced management team
- Partnerships to expand R&D capabilities
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Regulatory risks associated with drug approvals
- Commercialization risks if products are approved
Opportunities
- Expanding pipeline through acquisitions or partnerships
- Successful clinical trial results leading to regulatory approvals
- Growing demand for rare disease and oncology therapies
- Potential for breakthrough therapies in areas with unmet medical needs
Threats
- Clinical trial failures
- Regulatory rejections
- Competition from larger pharmaceutical companies
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Grifols (GRFS)
- Roche (RHHBY)
Competitive Landscape
Mereo BioPharma faces strong competition from larger, more established pharmaceutical companies with greater financial resources and broader product portfolios. Its success depends on clinical trial outcomes and securing regulatory approvals for its key assets.
Major Acquisitions
OnKure
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: To expand Mereo's pipeline with oncology assets and expertise. The consideration consisted of the issuance of ADSs representing approximately 20% of the outstanding ADSs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are dependent on specific financial data over the past years.
Future Projections: Future projections depend on analyst estimates and require access to financial databases. These cannot be generated without the data.
Recent Initiatives: Recent initiatives include the merger with OnKure, focusing on their oncology assets and advancement of Alvelestat through Phase 3 trials.
Summary
Mereo BioPharma is a clinical-stage company focused on rare diseases and oncology. The merger with OnKure provides pipeline diversification. Clinical trial success of Alvelestat and Etigilimab are key to future growth. Competition from established players and funding constraints pose significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports, industry analysis reports, financial news sources.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mereo BioPharma Group PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-04-24 | Co-Founder, CEO & Executive Director Dr. Denise Vera Scots-Knight Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.mereobiopharma.com |
Full time employees 36 | Website https://www.mereobiopharma.com | ||
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.